PTCT
PTC THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$68.97
+1.25%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.2B | 1.7B | 806.8M | 937.8M | 698.8M |
| Cost of Revenue | 87.9M | 71.8M | 57.4M | 65.5M | 44.7M |
| Gross Profit | 1.1B | 1.7B | 749.4M | 872.3M | 654.1M |
| Operating Expenses | |||||
| R&D Expense | 438.5M | 455.2M | 534.5M | 666.6M | 651.5M |
| SG&A Expense | 347.4M | 347.1M | 300.9M | 332.5M | 326.0M |
| General & Admin Expense | 80.1M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 143.4M | — | 216.6M | 312.7M | 124.0M |
| Total Operating Expenses | 929.3M | 802.4M | 1.1B | 1.3B | 1.1B |
| Cost and Expenses | 1.0B | 874.1M | 1.1B | 1.4B | 1.1B |
| Operating Income (EBIT) | 138.4M | 856.5M | (302.6M) | (439.5M) | (447.4M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 198.6M | 152.2M | 167.0M | 129.2M | 90.9M |
| Net Interest Income | (198.6M) | (152.2M) | (167.0M) | (129.2M) | (90.9M) |
| Other Non-Op Income/Expense | (223.4M) | (159.9M) | (60.5M) | (256.6M) | (140.1M) |
| Non-Operating Income (excl Interest) | 24.9M | 7.7M | (106.4M) | 127.4M | 49.2M |
| EBT (Pre-Tax Income) | (85.1M) | 696.6M | (363.1M) | (696.1M) | (587.5M) |
| Income Tax Expense | 20.9M | 14.0M | 176.0K | (69.5M) | (28.5M) |
| Bottom Line | |||||
| Net Income | (106.0M) | 682.6M | (363.3M) | (626.6M) | (559.0M) |
| Earnings from Cont. Ops | (106.0M) | 682.6M | (363.3M) | (626.6M) | (559.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (106.0M) | 682.6M | (363.3M) | (626.6M) | (559.0M) |
| Per Share | |||||
| Basic EPS | ($1.31) | $8.58 | ($4.73) | ($8.37) | ($7.79) |
| Diluted EPS | ($1.40) | $7.78 | ($4.73) | ($8.37) | ($7.79) |
| Revenue Per Share | $13.84 | $21.76 | $10.50 | $12.53 | $9.74 |
| Shares | |||||
| Basic Shares Outstanding | 83.5M | 79.5M | 76.8M | 74.8M | 71.7M |
| Diluted Shares Outstanding | 83.5M | 88.3M | 76.8M | 74.8M | 71.7M |
| Profitability Metrics | |||||
| EBITDA | 174.5M | 887.7M | (120.5M) | (330.3M) | (367.8M) |
| D&A | 61.0M | 38.8M | 75.7M | 236.6M | 128.8M |
| EBIT | 113.5M | 848.8M | (196.1M) | (566.9M) | (496.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026